[{"address1": "2929 7th Street", "address2": "Suite 105", "city": "Berkeley", "state": "CA", "zip": "94710", "country": "United States", "phone": "510 982 6030", "website": "https://cariboubio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.", "fullTimeEmployees": 147, "companyOfficers": [{"maxAge": 1, "name": "Dr. Rachel E. Haurwitz Ph.D.", "age": 38, "title": "Co-Founder, CEO, President & Director", "yearBorn": 1986, "fiscalYear": 2024, "totalPay": 832920, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Timothy P. Kelly M.B.A.", "age": 55, "title": "Chief Technology Officer", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 730050, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Steven B. Kanner Ph.D.", "age": 64, "title": "Chief Scientific Officer", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 668622, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Barbara G. McClung Esq., J.D.", "age": 69, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1955, "fiscalYear": 2024, "totalPay": 668622, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sriram  Ryali M.B.A.", "age": 42, "title": "Chief Financial Officer", "yearBorn": 1982, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Poon", "title": "Vice President of Operations & Information Technology", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Fischesser", "title": "Interim Principal Accounting Officer & Controller", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amy  Figueroa C.F.A.", "title": "Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Reigin  Zawadzki", "title": "Chief People Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ruhi A. Khan M.B.A.", "age": 49, "title": "Chief Business Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 573900, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 5, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.16, "open": 1.14, "dayLow": 1.03, "dayHigh": 1.155, "regularMarketPreviousClose": 1.16, "regularMarketOpen": 1.14, "regularMarketDayLow": 1.03, "regularMarketDayHigh": 1.155, "payoutRatio": 0.0, "beta": 2.362, "forwardPE": -0.5326633, "volume": 1259362, "regularMarketVolume": 1230094, "averageVolume": 1042284, "averageVolume10days": 1097310, "averageDailyVolume10Day": 1097310, "bid": 0.8136, "ask": 1.34, "bidSize": 2, "askSize": 2, "marketCap": 98584872, "fiftyTwoWeekLow": 0.66, "fiftyTwoWeekHigh": 3.0, "priceToSalesTrailing12Months": 9.939995, "fiftyDayAverage": 0.88686, "twoHundredDayAverage": 1.5602, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -83656120, "profitMargins": 0.0, "floatShares": 83939443, "sharesOutstanding": 93004600, "sharesShort": 9494724, "sharesShortPriorMonth": 9480437, "sharesShortPreviousMonthDate": 1744675200, "dateShortInterest": 1747267200, "sharesPercentSharesOut": 0.1021, "heldPercentInsiders": 0.09827, "heldPercentInstitutions": 0.53395003, "shortRatio": 9.22, "shortPercentOfFloat": 0.1069, "impliedSharesOutstanding": 101779000, "bookValue": 2.336, "priceToBook": 0.4537671, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -147862000, "trailingEps": -1.62, "forwardEps": -1.99, "enterpriseToRevenue": -8.435, "enterpriseToEbitda": 0.541, "52WeekChange": -0.50582755, "SandP52WeekChange": 0.1189177, "quoteType": "EQUITY", "currentPrice": 1.06, "targetHighPrice": 32.0, "targetLowPrice": 1.0, "targetMeanPrice": 9.14286, "targetMedianPrice": 6.0, "recommendationKey": "none", "numberOfAnalystOpinions": 7, "totalCash": 208464992, "totalCashPerShare": 2.241, "ebitda": -154644992, "totalDebt": 26224000, "quickRatio": 7.413, "currentRatio": 7.628, "totalRevenue": 9918000, "debtToEquity": 12.072, "revenuePerShare": 0.109, "returnOnAssets": -0.29212, "returnOnEquity": -0.5276, "grossProfits": -119761000, "freeCashflow": -82507872, "operatingCashflow": -137722000, "revenueGrowth": -0.031, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -18.23757, "financialCurrency": "USD", "symbol": "CRBU", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "postMarketChangePercent": 2.8302, "postMarketPrice": 1.09, "postMarketChange": 0.0300001, "regularMarketChange": -0.1, "regularMarketDayRange": "1.03 - 1.155", "shortName": "Caribou Biosciences, Inc.", "longName": "Caribou Biosciences, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1627047000000, "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1042284, "fiftyTwoWeekLowChange": 0.39999992, "fiftyTwoWeekLowChangePercent": 0.60606045, "fiftyTwoWeekRange": "0.66 - 3.0", "fiftyTwoWeekHighChange": -1.94, "fiftyTwoWeekHighChangePercent": -0.6466667, "fiftyTwoWeekChangePercent": -50.582756, "earningsTimestamp": 1746734642, "earningsTimestampStart": 1755028800, "earningsTimestampEnd": 1755028800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.62, "epsForward": -1.99, "epsCurrentYear": -1.64, "corporateActions": [], "postMarketTime": 1748649087, "regularMarketTime": 1748635201, "exchange": "NMS", "messageBoardId": "finmb_272189231", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -8.62069, "regularMarketPrice": 1.06, "marketState": "CLOSED", "priceEpsCurrentYear": -0.64634144, "fiftyDayAverageChange": 0.17313993, "fiftyDayAverageChangePercent": 0.19522803, "twoHundredDayAverageChange": -0.50020003, "twoHundredDayAverageChangePercent": -0.32059994, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-07-23", "cryptoTradeable": false, "displayName": "Caribou Biosciences", "trailingPegRatio": null, "__fetch_time": "2025-05-31"}]